Chronic conditions reshape Zurich’s Australian claims profile
The figure, drawn from Zurich’s retail, group, and direct claims across total and permanent disability (TPD), income protection,…
UK lags behind global countries in managing chronic health: Zurich
The provider has published its latest report, The Value of Chronic Care, which analysed all 38 countries of…
Novartis Cosentyx® PMR data in New England Journal of
Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid use; safety consistent…
Novartis RemIND data at EAACI show Rhapsido® potential as
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable…
Novartis to highlight Rhapsido® data across multiple
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be…
Novartis Cosentyx® PMR data in New England Journal of
Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid use; safety consistent…
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted…
Novartis data at EULAR 2026 demonstrates momentum for broad
New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted…
Novartis Rhapsido® receives European Commission approval
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly…
Novartis presents new data on early symptom relief and
New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous…
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous…
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a…